<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5539">
  <stage>Registered</stage>
  <submitdate>19/08/2009</submitdate>
  <approvaldate>19/08/2009</approvaldate>
  <nctid>NCT00962975</nctid>
  <trial_identification>
    <studytitle>A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>PP22612</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - peginterferon alfa-2a [Pegasys]

Experimental: Single Arm - 


Treatment: drugs: peginterferon alfa-2a [Pegasys]
dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The longitudinal effect on HBV-related markers: viral load, viral antigen/antibody, viral sequence, cellular and humoral immune responses, RNA</outcome>
      <timepoint>assessed every 2 months on treatment (not exceeding maximum approved duration), and up to week 24 of follow-up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability: AEs, laboratory parameters, vital signs, concomitant medications</outcome>
      <timepoint>assessed every 2 months on treatment and up to week 24 of follow-up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  adult patients &gt;/=18 years of age

          -  previous participation in other donor protocol

          -  chronic hepatitis B

          -  no other anti-HBV treatment after completion of previous donor protocol

          -  female patients and female partners of male patients must use at least two methods of
             contraception until 28 days after completion of study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  hepatic decompensation (Child-Pugh class B and C)

          -  antiviral, antineoplastic or immunomodulatory treatment

          -  evidence of alcohol and/or drug abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>29</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>In this open-label multicenter study the long-term effect of Pegasys monotherapy on
      pharmacodynamic HBV-related markers will be investigated in patients with chronic hepatitis
      B. Eligible patients will have completed treatment on another donor protocol (e.g. PP22512)
      and will receive Pegasys at an appropriate dose based on the standard of care (180mcg sc once
      weekly) for up to 48 weeks. Target sample size is &lt;100.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00962975</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>